Chinese expert consensus recommendations for management of bone health in female patients with early breast cancer (2022 edition)

Society of Breast Cancer of China Anti-Cancer Association The; Cancer Study Group Along Yangtze River Breast

doi:10.19401/j.cnki.1007-3639.2022.03.011

您当前的位置：

首页 >

文章列表页 >

Chinese expert consensus recommendations for management of bone health in female patients with early breast cancer (2022 edition)

Guideline and Consensus | 更新时间：2025-12-31

- Chinese expert consensus recommendations for management of bone health in female patients with early breast cancer (2022 edition)
- China Oncology Vol. 32, Issue 3, Pages: 274-286(2022)
- 作者机构：
- 作者简介：
- 基金信息：
- DOI：10.19401/j.cnki.1007-3639.2022.03.011
  CLC： R737.9
- Received：17 January 2022，
  
  Published：30 March 2022
- 稿件说明：
移动端阅览
Society of Breast Cancer of China Anti-Cancer Association The, Cancer Study Group Along Yangtze River Breast. Chinese expert consensus recommendations for management of bone health in female patients with early breast cancer (2022 edition)[J]. China Oncology, 2022, 32(3): 274-286.
DOI：

Society of Breast Cancer of China Anti-Cancer Association The, Cancer Study Group Along Yangtze River Breast. Chinese expert consensus recommendations for management of bone health in female patients with early breast cancer (2022 edition)[J]. China Oncology, 2022, 32(3): 274-286. DOI： 10.19401/j.cnki.1007-3639.2022.03.011.

摘要

早期乳腺癌女性患者的骨健康管理包括骨丢失的管理和骨转移的预防。随着早期乳腺癌患者生存期不断延长

这些患者的骨健康问题受到广泛关注

但目前临床上尚无系统的管理方案及诊疗措施。因此

中国抗癌协会乳腺癌专业委员会和长江学术带乳腺联盟组织相关专家

基于国内外指南及循证医学证据

深入探讨并制定了《早期乳腺癌女性患者的骨健康管理中国专家共识（2022年版）》

希望通过本共识规范早期乳腺癌患者的骨健康管理。

Abstract

The management of bone health in female patients with early breast cancer includes managing bone loss and preventing bone metastasis. As the overall survival of patients with early breast cancer continues to increase

bone health is getting extensive attention. However

there is no specific consensus in China on the methods and strategies of management and treatment. Based on the guideline and the substantial evidence based medicine (EBM)

the Society of Breast Cancer of China Anti-Cancer Association and Breast Cancer Study Group Along Yangtze River thoroughly discussed and formulated the Chinese expert consensus recommendations for management of bone health in female patients with early breast cancer (2022 edition)

in order to further standardize the management of patient’s bone health.

关键词

Keywords

references

FERLAY J , COLOMBET M , SOERJOMATARAM I , et al . Cancer statistics for the year 2020: an overview [J ] . Int J Cancer , 2021 . [Online ahead of print ]

HOWLADER N , ALTEKRUSE S F , LI C I , et al . US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status [J ] . J Natl Cancer Inst , 2014 , 106(5): dju055.

RIZZOLI R , BISCHOFF-FERRARI H , DAWSON-HUGHES B , et al . Nutrition and bone health in women after the menopause [J ] . Womens Health (Lond) , 2014 , 10 ( 6 ): 599 - 608 .

DIANA A N , CARLINO F , GIUNTA E F , et al . Cancer treatment-induced bone loss (CTIBL): state of the art and proper management in breast cancer patients on endocrine therapy [J ] . Curr Treat Options Oncol , 2021 , 22 ( 5 ): 45 . DOI: 10.1007/s11864-021-00835-2 http://doi.org/10.1007/s11864-021-00835-2 https://doi.org/10.1007/s11864-021-00835-2 https://doi.org/10.1007/s11864-021-00835-2

RACHNER T D , COLEMAN R , HADJI P , et al . Bone health during endocrine therapy for cancer [J ] . Lancet Diabetes Endocrinol , 2018 , 6 ( 11 ): 901 - 910 . DOI: 10.1016/S2213-8587(18)30047-0 http://doi.org/10.1016/S2213-8587(18)30047-0 https://linkinghub.elsevier.com/retrieve/pii/S2213858718300470 https://linkinghub.elsevier.com/retrieve/pii/S2213858718300470

LEE Y K , LEE E G , KIM H Y , et al . Osteoporotic fractures of the spine, hip, and other locations after adjuvant endocrine therapy with aromatase inhibitors in breast cancer patients: a meta-analysis [J ] . J Korean Med Sci , 2020 , 35 ( 46 ): e403 . DOI: 10.3346/jkms.2020.35.e403 http://doi.org/10.3346/jkms.2020.35.e403 https://jkms.org/DOIx.php?id=10.3346/jkms.2020.35.e403 https://jkms.org/DOIx.php?id=10.3346/jkms.2020.35.e403

BODY J J . Increased fracture rate in women with breast cancer: a review of the hidden risk [J ] . BMC Cancer , 2011 , 11 : 384 . DOI: 10.1186/1471-2407-11-384 http://doi.org/10.1186/1471-2407-11-384 http://bmccancer.biomedcentral.com/articles/10.1186/1471-2407-11-384 http://bmccancer.biomedcentral.com/articles/10.1186/1471-2407-11-384

CLYNES M A , HARVEY N C , CURTIS E M , et al . The epidemiology of osteoporosis [J ] . Br Med Bull , 2020 , 133 ( 1 ): 105 - 117 .

RASHKI KEMMAK A , REZAPOUR A , JAHANGIRI R , et al . Economic burden of osteoporosis in the world: a systematic review [J ] . Med J Islam Repub Iran , 2020 , 34 : 154 .

KEY T , APPLEBY P , BARNES I , et al . Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies [J ] . J Natl Cancer Inst , 2002 , 94 ( 8 ): 606 - 616 . DOI: 10.1093/jnci/94.8.606 http://doi.org/10.1093/jnci/94.8.606 https://academic.oup.com/jnci/article-lookup/doi/10.1093/jnci/94.8.606 https://academic.oup.com/jnci/article-lookup/doi/10.1093/jnci/94.8.606

FRANCIS P A , PAGANI O , FLEMING G F , et al . Tailoring adjuvant endocrine therapy for premenopausal breast cancer [J ] . N Engl J Med , 2018 , 379 ( 2 ): 122 - 137 . DOI: 10.1056/NEJMoa1803164 http://doi.org/10.1056/NEJMoa1803164 http://www.nejm.org/doi/10.1056/NEJMoa1803164 http://www.nejm.org/doi/10.1056/NEJMoa1803164

CUZICK J , SESTAK I , BAUM M , et al . Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial [J ] . Lancet Oncol , 2010 , 11 ( 12 ): 1135 - 1141 . DOI: 10.1016/S1470-2045(10)70257-6 http://doi.org/10.1016/S1470-2045(10)70257-6 https://linkinghub.elsevier.com/retrieve/pii/S1470204510702576 https://linkinghub.elsevier.com/retrieve/pii/S1470204510702576

REGAN M M , NEVEN P , GIOBBIE-HURDER A , et al . Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8.1 years median follow-up [J ] . Lancet Oncol , 2011 , 12 ( 12 ): 1101 - 1108 . DOI: 10.1016/S1470-2045(11)70270-4 http://doi.org/10.1016/S1470-2045(11)70270-4 https://linkinghub.elsevier.com/retrieve/pii/S1470204511702704 https://linkinghub.elsevier.com/retrieve/pii/S1470204511702704

NICKS K M , FOWLER T W , AKEL N S , et al . Bone turnover across the menopause transition: the role of gonadal inhibins [J ] . Ann N Y Acad Sci , 2010 , 1192 : 153 - 160 . DOI: 10.1111/j.1749-6632.2009.05349.x http://doi.org/10.1111/j.1749-6632.2009.05349.x https://onlinelibrary.wiley.com/doi/10.1111/j.1749-6632.2009.05349.x https://onlinelibrary.wiley.com/doi/10.1111/j.1749-6632.2009.05349.x

FOGELMAN I , BLAKE G M , BLAMEY R , et al . Bone mineral density in premenopausal women treated for node-positive early breast cancer with 2 years of goserelin or 6 months of cyclophosphamide, methotrexate and 5-fluorouracil (CMF) [J ] . Osteoporos Int , 2003 , 14 ( 12 ): 1001 - 1006 . DOI: 10.1007/s00198-003-1508-y http://doi.org/10.1007/s00198-003-1508-y http://link.springer.com/10.1007/s00198-003-1508-y http://link.springer.com/10.1007/s00198-003-1508-y

HADJI P , ZILLER M , KIEBACK D G , et al . Effects of exemestane and tamoxifen on bone health within the tamoxifen exemestane adjuvant multicentre (TEAM) trial: results of a German, 12-month, prospective, randomised substudy [J ] . Ann Oncol , 2009 , 20 ( 7 ): 1203 - 1209 . DOI: 10.1093/annonc/mdn762 http://doi.org/10.1093/annonc/mdn762 https://linkinghub.elsevier.com/retrieve/pii/S0923753419409964 https://linkinghub.elsevier.com/retrieve/pii/S0923753419409964

HADJI P , GNANT M , BODY J J , et al . Cancer treatment-induced bone loss in premenopausal women: a need for therapeutic intervention? [J ] . Cancer Treat Rev , 2012 , 38 ( 6 ): 798 - 806 . DOI: 10.1016/j.ctrv.2012.02.008 http://doi.org/10.1016/j.ctrv.2012.02.008 https://linkinghub.elsevier.com/retrieve/pii/S0305737212000291 https://linkinghub.elsevier.com/retrieve/pii/S0305737212000291

NUZZO F , GALLO C , LASTORIA S , et al . Bone effect of adjuvant tamoxifen, letrozole or letrozole plus zoledronic acid in early-stage breast cancer: the randomized phase 3 HOBOE study [J ] . Ann Oncol , 2012 , 23 ( 8 ): 2027 - 2033 . DOI: 10.1093/annonc/mdr600 http://doi.org/10.1093/annonc/mdr600 https://linkinghub.elsevier.com/retrieve/pii/S0923753419381086 https://linkinghub.elsevier.com/retrieve/pii/S0923753419381086

BURSTEIN H J , LACCHETTI C , ANDERSON H , et al . Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: ASCO clinical practice guideline focused update [J ] . J Clin Oncol , 2019 , 37 ( 5 ): 423 - 438 .

马远征 , 王以朋 , 刘强 , 等 . 中国老年骨质疏松诊疗指南(2018) [J ] . 中国老年学杂志 , 2019 , 39 ( 11 ): 2557 - 2575 .

MA Y Z , WANG Y P , LIU Q , et al . 2018 China guideline for the diagnosis and treatment of senile osteoporosis [J ] . Chin J Gerontol , 2019 , 39 ( 11 ): 2557 - 2575 .

COLEMAN R , HADJI P , BODY J J , et al . Bone health in cancer: ESMO clinical practice guidelines [J ] . Ann Oncol , 2020 , 31 ( 12 ): 1650 - 1663 . DOI: 10.1016/j.annonc.2020.07.019 http://doi.org/10.1016/j.annonc.2020.07.019 https://linkinghub.elsevier.com/retrieve/pii/S0923753420399956 https://linkinghub.elsevier.com/retrieve/pii/S0923753420399956

中国抗癌协会乳腺癌专业委员会 . 中国抗癌协会乳腺癌诊治指南与规范(2021年版) [J ] . 中国癌症杂志 , 2021 , 31 ( 10 ): 954 - 1040 .

The Society of Breast Cancer China Anti-Cancer Association . Guidelines for breast cancer diagnosis and treatment by China Anti-Cancer Association (2021 edition) [J ] . China Oncol , 2021 , 31 ( 10 ): 954 - 1040 .

HANDFORTH C , D'ORONZO S , COLEMAN R , et al . Cancer treatment and bone health [J ] . Calcif Tissue Int , 2018 , 102 ( 2 ): 251 - 264 . DOI: 10.1007/s00223-017-0369-x http://doi.org/10.1007/s00223-017-0369-x https://doi.org/10.1007/s00223-017-0369-x https://doi.org/10.1007/s00223-017-0369-x

WEAVER C M , ALEXANDER D D , BOUSHEY C J , et al . Calcium plus vitamin D supplementation and risk of fractures: an updated meta-analysis from the National Osteoporosis Foundation [J ] . Osteoporos Int , 2016 , 27 ( 1 ): 367 - 376 . DOI: 10.1007/s00198-015-3386-5 http://doi.org/10.1007/s00198-015-3386-5 https://link.springer.com/10.1007/s00198-015-3386-5 https://link.springer.com/10.1007/s00198-015-3386-5

HADJI P , AAPRO M S , BODY J J , et al . Management of aromatase inhibitor-associated bone loss in postmenopausal women with breast cancer: practical guidance for prevention and treatment [J ] . Ann Oncol , 2011 , 22 ( 12 ): 2546 - 2555 . DOI: 10.1093/annonc/mdr017 http://doi.org/10.1093/annonc/mdr017 https://linkinghub.elsevier.com/retrieve/pii/S0923753419343480 https://linkinghub.elsevier.com/retrieve/pii/S0923753419343480

中华医学会骨质疏松和骨矿盐疾病分会 . 原发性骨质疏松症诊疗指南(2017) [J ] . 中国全科医学 , 2017 , 20 ( 32 ): 3963 - 3982 . DOI: 10.3969/j.issn.1007-9572.2017.00.118 http://doi.org/10.3969/j.issn.1007-9572.2017.00.118

Chinese Society of Osteoporosis and Bone Mineral Research . Guidelines for the diagnosis and treatment of primary osteoporosis (2017) [J ] . Chin Gen Pract , 2017 , 20 ( 32 ): 3963 - 3982 .

邵志敏 , 沈镇宙 , 徐兵河 . 乳腺肿瘤学 [M ] . 上海 : 复旦大学出版社 , 2013 .

SHAO Z M , SHEN Z Z , XU B H . Breast oncology [M ] . Shanghai : Fudan University Press , 2013 .

MEI M , XIANG Z , YANG J , et al . Efficacy of zoledronic acid for prevention of bone loss in early-stage breast cancer patients receiving adjuvant therapy: a meta-analysis of 13 randomized controlled trials [J ] . Curr Probl Cancer , 2020 , 44 ( 2 ): 100507 .

中国医师协会肿瘤医师分会乳腺癌学组 , 中国抗癌协会国际医疗交流分会 . 骨改良药物安全性管理专家共识 [J ] . 中华肿瘤杂志 , 2021 , 43 ( 6 ): 622 - 628 .

Breast Cancer Division , Oncologist Branch of Chinese Medical Association; International Medical Exchange Branch of Chinese Anti-Cancer Association. Expert consensus on safety management of bone-modifying agents [J ] . Chin J Oncol , 2021 , 43 ( 6 ): 622 - 628 .

VEHMANEN L K , ELOMAA I , BLOMQVIST C P , et al . The effect of ovarian dysfunction on bone mineral density in breast cancer patients 10 years after adjuvant chemotherapy [J ] . Acta Oncol , 2014 , 53 ( 1 ): 75 - 79 . DOI: 10.3109/0284186X.2013.792992 http://doi.org/10.3109/0284186X.2013.792992 http://www.tandfonline.com/doi/full/10.3109/0284186X.2013.792992 http://www.tandfonline.com/doi/full/10.3109/0284186X.2013.792992

GNANT M F X , MLINERITSCH B , LUSCHIN-EBENGREUTH G , et al . Zoledronic acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: a report from the Austrian Breast and Colorectal Cancer Study Group [J ] . J Clin Oncol , 2007 , 25 ( 7 ): 820 - 828 . DOI: 10.1200/JCO.2005.02.7102 http://doi.org/10.1200/JCO.2005.02.7102 http://ascopubs.org/doi/10.1200/JCO.2005.02.7102 http://ascopubs.org/doi/10.1200/JCO.2005.02.7102

GNANT M , MLINERITSCH B , LUSCHIN-EBENGREUTH G , et al . Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy [J ] . Lancet Oncol , 2008 , 9 ( 9 ): 840 - 849 . DOI: 10.1016/S1470-2045(08)70204-3 http://doi.org/10.1016/S1470-2045(08)70204-3 https://linkinghub.elsevier.com/retrieve/pii/S1470204508702043 https://linkinghub.elsevier.com/retrieve/pii/S1470204508702043

LESTER J E , DODWELL D , PUROHIT O P , et al . Prevention of anastrozole-induced bone loss with monthly oral ibandronate during adjuvant aromatase inhibitor therapy for breast cancer [J ] . Clin Cancer Res , 2008 , 14 ( 19 ): 6336 - 6342 . DOI: 10.1158/1078-0432.CCR-07-5101 http://doi.org/10.1158/1078-0432.CCR-07-5101 http://clincancerres.aacrjournals.org/lookup/doi/10.1158/1078-0432.CCR-07-5101 http://clincancerres.aacrjournals.org/lookup/doi/10.1158/1078-0432.CCR-07-5101

LESTER J E , DODWELL D , BROWN J E , et al . Prevention of anastrozole induced bone loss with monthly oral ibandronate: final 5 year results from the ARIBON trial [J ] . J Bone Oncol , 2012 , 1 ( 2 ): 57 - 62 . DOI: 10.1016/j.jbo.2012.06.002 http://doi.org/10.1016/j.jbo.2012.06.002 https://linkinghub.elsevier.com/retrieve/pii/S2212137412000206 https://linkinghub.elsevier.com/retrieve/pii/S2212137412000206

GNANT M , PFEILER G , DUBSKY P C , et al . Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial [J ] . Lancet , 2015 , 386 ( 9992 ): 433 - 443 . DOI: 10.1016/S0140-6736(15)60995-3 http://doi.org/10.1016/S0140-6736(15)60995-3 https://linkinghub.elsevier.com/retrieve/pii/S0140673615609953 https://linkinghub.elsevier.com/retrieve/pii/S0140673615609953

ELLIS G K , BONE H G , CHLEBOWSKI R , et al . Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer [J ] . J Clin Oncol , 2008 , 26 ( 30 ): 4875 - 4882 . DOI: 10.1200/JCO.2008.16.3832 http://doi.org/10.1200/JCO.2008.16.3832 http://ascopubs.org/doi/10.1200/JCO.2008.16.3832 http://ascopubs.org/doi/10.1200/JCO.2008.16.3832

SHAPIRO C L , VAN POZNAK C , LACCHETTI C , et al . Management of osteoporosis in survivors of adult cancers with nonmetastatic disease: ASCO clinical practice guideline [J ] . J Clin Oncol , 2019 , 37 ( 31 ): 2916 - 2946 . DOI: 10.1200/JCO.19.01696 http://doi.org/10.1200/JCO.19.01696 https://ascopubs.org/doi/10.1200/JCO.19.01696 https://ascopubs.org/doi/10.1200/JCO.19.01696

NCCN clinical practice guidelines in oncology (breast cancer) (version 5.2021) [EB/OL ] . [ 2021 - 06 - 28 ] . http://www.nccn.org/patients http://www.nccn.org/patients http://www.nccn.org/patients.

BUNDRED N J , CAMPBELL I D , DAVIDSON N , et al . Effective inhibition of aromatase inhibitor-associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: ZO-FAST study results [J ] . Cancer , 2008 , 112 ( 5 ): 1001 - 1010 . DOI: 10.1002/(ISSN)1097-0142 http://doi.org/10.1002/(ISSN)1097-0142 http://doi.wiley.com/10.1002/%28ISSN%291097-0142 http://doi.wiley.com/10.1002/%28ISSN%291097-0142

EIDTMANN H , DE BOER R , BUNDRED N , et al . Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST study [J ] . Ann Oncol , 2010 , 21 ( 11 ): 2188 - 2194 . DOI: 10.1093/annonc/mdq217 http://doi.org/10.1093/annonc/mdq217 https://linkinghub.elsevier.com/retrieve/pii/S0923753419395341 https://linkinghub.elsevier.com/retrieve/pii/S0923753419395341

COLEMAN R , DE BOER R , EIDTMANN H , et al . Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results [J ] . Ann Oncol , 2013 , 24 ( 2 ): 398 - 405 . DOI: 10.1093/annonc/mds277 http://doi.org/10.1093/annonc/mds277 https://linkinghub.elsevier.com/retrieve/pii/S0923753419368425 https://linkinghub.elsevier.com/retrieve/pii/S0923753419368425

DERENNE S , AMIOT M , BARILLÉ S , et al . Zoledronate is a potent inhibitor of myeloma cell growth and secretion of IL-6 and MMP-1 by the tumoral environment [J ] . J Bone Miner Res , 1999 , 14 ( 12 ): 2048 - 2056 . DOI: 10.1359/jbmr.1999.14.12.2048 http://doi.org/10.1359/jbmr.1999.14.12.2048 http://doi.wiley.com/10.1359/jbmr.1999.14.12.2048 http://doi.wiley.com/10.1359/jbmr.1999.14.12.2048

APARICIO A , GARDNER A , TU Y , et al . In vitro cytoreductive effects on multiple myeloma cells induced by bisphosphonates [J ] . Leukemia , 1998 , 12 ( 2 ): 220 - 229 . DOI: 10.1038/sj.leu.2400892 http://doi.org/10.1038/sj.leu.2400892 https://doi.org/10.1038/sj.leu.2400892 https://doi.org/10.1038/sj.leu.2400892

FROMIGUE O , LAGNEAUX L , BODY J J . Bisphosphonates induce breast cancer cell death in vitro [J ] . J Bone Miner Res , 2000 , 15 ( 11 ): 2211 - 2221 . DOI: 10.1359/jbmr.2000.15.11.2211 http://doi.org/10.1359/jbmr.2000.15.11.2211 http://doi.wiley.com/10.1359/jbmr.2000.15.11.2211 http://doi.wiley.com/10.1359/jbmr.2000.15.11.2211

SENARATNE S G , PIRIANOV G , MANSI J L , et al . Bisphosphonates induce apoptosis in human breast cancer cell lines [J ] . Br J Cancer , 2000 , 82 ( 8 ): 1459 - 1468 . DOI: 10.1054/bjoc.1999.1131 http://doi.org/10.1054/bjoc.1999.1131 http://www.nature.com/doifinder/10.1054/bjoc.1999.1131 http://www.nature.com/doifinder/10.1054/bjoc.1999.1131

BOISSIER S , FERRERAS M , PEYRUCHAUD O , et al . Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases [J ] . Cancer Res , 2000 , 60 ( 11 ): 2949 - 2954 .

WOOD J , BONJEAN K , RUETZ S , et al . Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid [J ] . J Pharmacol Exp Ther , 2002 , 302 ( 3 ): 1055 - 1061 . DOI: 10.1124/jpet.102.035295 http://doi.org/10.1124/jpet.102.035295 http://jpet.aspetjournals.org/lookup/doi/10.1124/jpet.102.035295 http://jpet.aspetjournals.org/lookup/doi/10.1124/jpet.102.035295

COLEMAN R , WOODWARD E , BROWN J , et al . Safety of zoledronic acid and incidence of osteonecrosis of the jaw (ONJ) during adjuvant therapy in a randomised phase Ⅲ trial (AZURE: BIG 01-04) for women with stage Ⅱ/Ⅲ breast cancer [J ] . Breast Cancer Res Treat , 2011 , 127 ( 2 ): 429 - 438 . DOI: 10.1007/s10549-011-1429-y http://doi.org/10.1007/s10549-011-1429-y http://link.springer.com/10.1007/s10549-011-1429-y http://link.springer.com/10.1007/s10549-011-1429-y

COLEMAN R , CAMERON D , DODWELL D , et al . Adjuvant zoledronic acid in patients with early breast cancer: final efficacy analysis of the AZURE (BIG 01/04) randomised open-label phase 3 trial [J ] . Lancet Oncol , 2014 , 15 ( 9 ): 997 - 1006 . DOI: 10.1016/S1470-2045(14)70302-X http://doi.org/10.1016/S1470-2045(14)70302-X https://linkinghub.elsevier.com/retrieve/pii/S147020451470302X https://linkinghub.elsevier.com/retrieve/pii/S147020451470302X

COLEMAN R , HALL A , ALBANELL J , et al . Effect of MAF amplification on treatment outcomes with adjuvant zoledronic acid in early breast cancer: a secondary analysis of the international, open-label, randomised, controlled, phase 3 AZURE (BIG 01/04) trial [J ] . Lancet Oncol , 2017 , 18 ( 11 ): 1543 - 1552 . DOI: 10.1016/S1470-2045(17)30603-4 http://doi.org/10.1016/S1470-2045(17)30603-4 https://linkinghub.elsevier.com/retrieve/pii/S1470204517306034 https://linkinghub.elsevier.com/retrieve/pii/S1470204517306034

COLEMAN R E , COLLINSON M , GREGORY W , et al . Benefits and risks of adjuvant treatment with zoledronic acid in stage Ⅱ/Ⅲ breast cancer. 10 years follow-up of the AZURE randomized clinical trial (BIG 01/04) [J ] . J Bone Oncol , 2018 , 13 : 123 - 135 . DOI: 10.1016/j.jbo.2018.09.008 http://doi.org/10.1016/j.jbo.2018.09.008 https://linkinghub.elsevier.com/retrieve/pii/S2212137418302628 https://linkinghub.elsevier.com/retrieve/pii/S2212137418302628

GNANT M , MLINERITSCH B , STOEGER H , et al . Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozol plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian Breast and Colorectal Cancer Study Group trial 12 [J ] . Ann Oncol , 2015 , 26 ( 2 ): 313 - 320 . DOI: 10.1093/annonc/mdu544 http://doi.org/10.1093/annonc/mdu544 https://linkinghub.elsevier.com/retrieve/pii/S0923753419313912 https://linkinghub.elsevier.com/retrieve/pii/S0923753419313912

PERRONE F , DE LAURENTIIS M , DE PLACIDO S , et al . Adjuvant zoledronic acid and letrozole plus ovarian function suppression in premenopausal breast cancer: HOBOE phase 3 randomised trial [J ] . Eur J Cancer , 2019 , 118 : 178 - 186 . DOI: 10.1016/j.ejca.2019.05.004 http://doi.org/10.1016/j.ejca.2019.05.004 https://linkinghub.elsevier.com/retrieve/pii/S0959804919302977 https://linkinghub.elsevier.com/retrieve/pii/S0959804919302977

FRIEDL T W P , FEHM T , MÜLLER V , et al . Prognosis of patients with early breast cancer receiving 5 years vs 2 years of adjuvant bisphosphonate treatment: a phase 3 randomized clinical trial [J ] . JAMA Oncol , 2021 , 7 ( 8 ): 1149 - 1157 . DOI: 10.1001/jamaoncol.2021.1854 http://doi.org/10.1001/jamaoncol.2021.1854 https://jamanetwork.com/journals/jamaoncology/fullarticle/2781088 https://jamanetwork.com/journals/jamaoncology/fullarticle/2781088

Early Breast Cancer Trialists' Collaborative Group (EBCTCG) . Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials [J ] . Lancet , 2015 , 386 ( 10001 ): 1353 - 1361 . DOI: 10.1016/S0140-6736(15)60908-4 http://doi.org/10.1016/S0140-6736(15)60908-4 https://linkinghub.elsevier.com/retrieve/pii/S0140673615609084 https://linkinghub.elsevier.com/retrieve/pii/S0140673615609084

HE M F , FAN W D , ZHANG X Q . Adjuvant zoledronic acid therapy for patients with early stage breast cancer: an updated systematic review and meta-analysis [J ] . J Hematol Oncol , 2013 , 6 ( 1 ): 80 . DOI: 10.1186/1756-8722-6-80 http://doi.org/10.1186/1756-8722-6-80 https://doi.org/10.1186/1756-8722-6-80 https://doi.org/10.1186/1756-8722-6-80

HUANG W W , HUANG C , LIU J , et al . Zoledronic acid as an adjuvant therapy in patients with breast cancer: a systematic review and meta-analysis [J ] . PLoS One , 2012 , 7 ( 7 ): e40783 . DOI: 10.1371/journal.pone.0040783 http://doi.org/10.1371/journal.pone.0040783 https://dx.plos.org/10.1371/journal.pone.0040783 https://dx.plos.org/10.1371/journal.pone.0040783

GNANT M , PFEILER G , STEGER G G , et al . Adjuvant denosumab in postmenopausal patients with hormone receptor-positive breast cancer (ABCSG-18): disease-free survival results from a randomised, double-blind, placebo-controlled, phase 3 trial [J ] . Lancet Oncol , 2019 , 20 ( 3 ): 339 - 351 . DOI: 10.1016/S1470-2045(18)30862-3 http://doi.org/10.1016/S1470-2045(18)30862-3 https://linkinghub.elsevier.com/retrieve/pii/S1470204518308623 https://linkinghub.elsevier.com/retrieve/pii/S1470204518308623

COLEMAN R , FINKELSTEIN D M , BARRIOS C , et al . Adjuvant denosumab in early breast cancer (D-CARE): an international, multicentre, randomised, controlled, phase 3 trial [J ] . Lancet Oncol , 2020 , 21 ( 1 ): 60 - 72 . DOI: 10.1016/S1470-2045(19)30687-4 http://doi.org/10.1016/S1470-2045(19)30687-4 https://linkinghub.elsevier.com/retrieve/pii/S1470204519306874 https://linkinghub.elsevier.com/retrieve/pii/S1470204519306874

EISEN A , SOMERFIELD M R , ACCORDINO M K , et al . Use of adjuvant bisphosphonates and other bone-modifying agents in breast cancer: ASCO-OH (CCO) guideline update [J ] . J Clin Oncol , 2022 . [Online ahead of print ]

GREGORY W , MARSHALL H , BELL R , et al . Adjuvant zoledronic acid (ZOL) in postmenopausal women with breast cancer and those rendered postmenopausal: results of a meta-analysis [J ] . J Clin Oncol , 2012 , 30 ( 15_suppl ): 513 .

Views

1832

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Construction of the prediction model of breast cancer bone metastasis based on machine learning

New progress and prospect of breast cancer bone metastasis research from mechanism to clinic

Comparative study of modified EDTA decalcification and acid decalcification in immunohistochemistry of breast cancer with bone metastasis

Guidelines for breast cancer diagnosis and treatment by China Anti-Cancer Association (2026 edition)

Progress and prospects of CENPA-driven chromosomal instability in breast cancer: mechanisms, prognostic implications, and therapeutic perspectives

Related Author

Fei OUYANG

Yang WANG

Yu CHEN

Guoqing PEI

Ling WANG

Yang ZHANG

Lei SHI

Jiahui WANG

Related Institution

Department of Orthopaedics, The First Affiliated Hospital of Air Force Medical University, Xi 'an

Department of Neurology, The First Affiliated Hospital of Air Force Medical University

Department of Health Statistics, Department of Military Preventive Medicine, Air Force Military Medical University

上海交通大学附属第六人民医院肿瘤内科

上海交通大学附属第六人民医院病理科

AI问答

⁰